Solaraze

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Solaraze

The foundational definition of Solaraze establishes its identity as a targeted, prescription-only medication formulated for topical application. This section defines its core characteristics, composition, pharmacological classification, and general therapeutic function, grounded in authoritative pharmaceutical data.

Property Description
Active ingredient Diclofenac Sodium
Form Topical Gel
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
Common use Local anti-inflammatory and pain relief
Origin Synthetic, Phenylacetic acid derivative

Defining Solaraze: Type and Classification

Solaraze is a dermatological product whose active ingredient is Diclofenac Sodium, which places it within the class of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). This preparation is a synthetic compound, chemically identified as a Phenylacetic acid derivative.

As a topical NSAID, its primary classification highlights its mechanism to counter inflammation. Diclofenac is a well-established NSAID, recognized across numerous clinical settings for its anti-inflammatory and analgesic properties. The Diclofenac Sodium molecule, which provides the therapeutic effect, is a synthetic agent, ensuring a precise and consistent pharmacological profile.


Composition and Physical Form (Topical Gel Monotherapy)

The medicine is supplied as a Topical Gel, an aqueous-alcoholic formulation intended for direct application to the skin's surface. It functions as a single-active-ingredient product or monotherapy, containing only the active compound Diclofenac Sodium.

The gel formulation for topical delivery is structured to facilitate the controlled penetration of the active substance through the skin. This delivery method is engineered for low systemic absorption, a defining feature that concentrates the medication’s activity locally at the site of administration, which differentiates it from NSAIDs designed for widespread distribution throughout the body. The specific formulation of Solaraze is clinically supported for effective dermal absorption of Diclofenac.


General Therapeutic Purpose and Local Action

The overall purpose of Solaraze is to provide local anti-inflammatory action and relief from associated discomfort through a targeted mechanism. This action is rooted in the fact that Diclofenac Sodium works as a cyclooxygenase (COX) inhibitor, which serves to interrupt the production of prostaglandins—the chemical mediators that signal and drive inflammatory processes. The medicine addresses inflammation and pain by chemically interrupting the body's pain signaling cascade. By focusing its action, the preparation offers relief that stems from reducing the underlying tissue inflammation.

Regulatory References

  1. Diclofenac Topical (arthritis pain): MedlinePlus Drug Information

What side effects are possible with Solaraze?

Possible Side Effects and Safety Information

The officially documented safety profile of Solaraze (Diclofenac Sodium Topical Gel) is characterized by highly frequent local adverse reactions, combined with mandatory warnings for the systemic risks associated with the Nonsteroidal Anti-Inflammatory Drug (NSAID) class.

Frequency-Classified Local Adverse Reactions

The majority of documented adverse effects are confined to the application site, reflecting the topical route of administration. These reactions are often observed at the start of treatment and may resolve over time.

Frequency Classification Associated Adverse Reactions (Dermatological)
Very Common (ge 1/10) Application site dermatitis (including contact dermatitis), dry skin, pruritus, erythema, scaling
Common (ge 1/100 to < 1/10) Rash, application site pain, headache
Rare (ge 1/10,000 to < 1/1,000) Bullous dermatitis

Systemic NSAID Warnings and Restrictions

Despite low systemic absorption, the active ingredient, Diclofenac Sodium, requires official regulatory warnings for serious adverse events linked to the NSAID class. These include the potential for serious cardiovascular thrombotic events (such as myocardial infarction and stroke) and severe gastrointestinal events (such as bleeding, ulceration, and perforation).

Key Safety Considerations:

  • Hypersensitivity: The medicine is contraindicated in individuals with a known hypersensitivity to diclofenac, aspirin, or other NSAIDs, or a history of aspirin-sensitive asthma.
  • Sunlight: Treated areas must avoid exposure to natural or artificial sunlight due to the potential for photosensitivity reactions.
  • Pregnancy: The gel is contraindicated in the third trimester of pregnancy due to the risk of premature closure of the fetal ductus arteriosus. The elderly are at greater risk for systemic NSAID-related adverse reactions.

This structure reflects the regulatory requirement to address both the common local effects and the serious, class-wide systemic risks of the drug.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose from the appropriate topical application of Solaraze (Diclofenac Sodium Topical Gel) is considered unlikely due to the formulation's low systemic absorption. However, a significant systemic overexposure can occur following accidental ingestion or grossly excessive application, which may lead to manifestations consistent with acute Nonsteroidal Anti-Inflammatory Drug (NSAID) toxicity.

Officially documented overdose presentations include gastrointestinal disturbances such as nausea, vomiting, stomach pain, and bleeding, as well as central nervous system effects such as drowsiness, lethargy, headache, and tinnitus.

Severe, life-threatening outcomes are documented in regulatory labeling and can include acute renal failure, gastrointestinal hemorrhage, and seizures. In these situations, fatalities have occurred rarely.

Immediate action is mandatory in cases of suspected overdose or accidental ingestion; regulatory guidance states to seek immediate medical attention and/or contact a poison control center.

Management of systemic overexposure is symptomatic and supportive, as no specific antidote is known. Intensive medical monitoring, including observation of vital signs and renal function, is required. Individuals with known impaired renal or hepatic function face an increased risk of severity in an overdose context.

Therapeutic Uses of Solaraze

What Solaraze Treats: Main Uses and Benefits

Solaraze is applied as a topical therapy for the management of high-risk skin conditions, focusing specifically on Actinic Keratosis (AK), which is a common pre-malignant growth caused by chronic sun exposure. This medication is commonly used to help with achieving clearance or resolution of these abnormal growths, and it plays a role in managing the risk associated with these pre-malignant lesions. A key therapeutic use is in field-directed therapy, where the goal is to manage the entire area of sun-damaged skin, treating both visible lesions and subclinical growths.

Therapeutic Contexts and Symptom Management

Patients commonly seek relief when experiencing symptoms related to localized discomfort, including soreness, tenderness, itching, and the rough, scaly texture of the affected patches. This topical therapy supports the overall management of high-risk growths and the discomfort they cause in sun-exposed areas. Solaraze assists with easing the impact of the lesions on routine activities and contributes to easing day-to-day comfort by managing the associated symptomatic burden.

Quick Fact: Relief for Localized Discomfort Solaraze is relevant for easing symptom clusters that may become intense or disruptive and is used in conditions involving localized discomfort.

Eligibility and Restrictions for Use

Who can and cannot use Solaraze?

Solaraze is strictly for use by adults aged 18 years and older for the treatment of Actinic Keratosis. The safety and effectiveness of the gel have not been established in pediatric patients under this age. While older adults may use the standard dose, caution is advised due to the potential for age-related NSAID-associated renal or cardiovascular issues.

Contraindicated Populations

Use of Solaraze is absolutely contraindicated for specific groups. This includes patients with a known hypersensitivity to diclofenac or any components of the gel, as well as those with a history of allergic reactions (such as asthma or urticaria) after taking aspirin or other NSAIDs. The medicine must also not be used in the setting of Coronary Artery Bypass Graft (CABG) surgery or on skin that is not intact, such as open wounds or infections.

Pregnancy and Condition Restrictions

Solaraze is contraindicated during the third trimester of pregnancy. Use between 20 and 30 weeks gestation must be limited to the lowest effective dose and shortest duration possible. Caution is also required for patients with severe heart failure, advanced renal disease, or a history of gastrointestinal ulceration or bleeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Solaraze (diclofenac sodium topical gel) exhibits a low potential for systemic drug-drug interactions due to its limited absorption through the skin. However, several interaction patterns are officially documented based on the drug's Nonsteroidal Anti-Inflammatory Drug (NSAID) class and its ability to influence systemic effects. No medicinal products are formally listed as contraindicated for co-administration in the interaction section of the regulatory label.


Documented Interaction Patterns

Interacting Substance/Class Official Interaction Statement
Oral NSAIDs Concomitant use with oral NSAIDs (including aspirin at analgesic/anti-inflammatory doses) is not generally recommended as it may lead to an increased risk of systemic adverse reactions.
Anticoagulants/Antiplatelets Use with drugs that interfere with hemostasis (e.g., warfarin, aspirin, SSRIs/SNRIs) requires monitoring due to a potentially increased risk of bleeding.
Antihypertensives Co-administration may diminish the blood pressure-lowering effect of ACE Inhibitors, ARBs, and Beta-Blockers.
Diuretics NSAIDs can reduce the natriuretic and diuretic effect of medications like Furosemide and Thiazides.
Other Medicines The gel may increase the serum concentration of drugs like Digoxin, Methotrexate, Cyclosporine, and Lithium.

Population-Specific Caution

When co-administered with ACE Inhibitors or ARBs, there is an official caution that the combination may result in a deterioration of renal function in specific populations, including the elderly, volume-depleted, or those with renal impairment. The regulatory profile does not specify any required time separation between doses or list interactions with food, alcohol, or supplements.

Mechanism of Action

Enzyme-Level Inhibition of Prostaglandin Synthesis

The core mechanism of Diclofenac Sodium involves the non-selective inhibition of Cyclooxygenase (COX) enzymes (COX-1 and COX-2). By blocking these enzymes, the drug prevents the conversion of arachidonic acid into prostaglandins (like PGE2) and other prostanoids. This action is relevant to systems where enzyme-mediated signaling is required for the synthesis of prostanoids, thereby modulating the chemical signaling of the localized response.

Influence on Peripheral Nociceptor Responsiveness

The resulting decrease in local prostaglandin concentration directly leads to the functional consequence of reduced nociceptor responsiveness. PGE2 typically acts to lower the activation threshold of peripheral sensory nerve endings (nociceptors). By reducing the availability of this mediator, the mechanism influences the signaling dynamics of peripheral nerve endings, leading to a higher nociceptor activation threshold and modulation of local tissue responses.

Dosage and Administration Information

How to Use Solaraze (Diclofenac Sodium 3% Gel)

Solaraze is a topical formulation with application guidelines to ensure correct use. The medication is delivered via the cutaneous route, meaning it is applied directly to the surface of the skin.


Administration and Dosing Schedule

Instruction Detail (Labeled Instruction)
Route of Administration Cutaneous (applied directly to the skin).
Dosing Schedule Apply 0.5 grams of gel (approximately a pea-sized amount) per 5 cm x 5 cm lesion site.
Maximum Daily Use The total quantity of gel used should not exceed 8 grams per day.
Frequency and Timing Applied to the affected area twice daily (morning and evening).
Course Duration The recommended duration of therapy is typically 60 to 90 days.

Procedural and Population-Specific Guidelines

The gel must be gently smoothed onto the skin to adequately cover the lesions, and contact with the eyes or mucous membranes must be avoided. After application, hands should be washed unless the hands themselves are the area being treated. The instructions state that the gel should not be used with an airtight occlusive dressing. If a dose is missed, the regular schedule should be resumed without applying a double amount.

For older adults, the usual adult dose may be applied, as no specific adjustment is stated in the label. Dosage recommendations for the pediatric population have not been established. A complete therapeutic effect may not be evident until up to 30 days following cessation of the 60 to 90-day treatment course.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Solaraze

This overview summarizes the available research concerning the clinical evaluation of Solaraze (diclofenac sodium 3% topical gel), focusing only on the structure and findings of studies as reported in regulatory and scientific literature.


Evidence for Use in Actinic Keratosis (AK)

The foundation of the research for Solaraze involves multiple Randomized, Double-Blind, Vehicle-Controlled Trials (RCTs). These are the core study designs used by regulators to evaluate prescription medicines. These core studies evaluated the status of treated lesions in patients applying the active diclofenac gel versus an inactive control gel (called the vehicle) to the skin. This research was studied for its application in managing non-hyperkeratotic, non-hypertrophic AK lesions on common sun-exposed areas such as the face, scalp, and forearms.

The main findings described in the studies reported differences in the clearance measurements between the active gel group and the vehicle control group when evaluated after a prescribed treatment period, typically 60 to 90 days. Research examined outcomes related to the overall status of the lesions, using the specific metrics defined in the study protocols. Some trials described patterns where longer treatment durations were associated with higher measurements of lesion clearance compared to shorter application periods.


Study Endpoints: What Outcomes Were Measured

Research explored several measurements, or endpoints, to monitor changes in the observed populations. One of the primary measurements was the assessment of the Complete Clearance Rate, which tracked the percentage of patients who met the study's predefined endpoint for 100% lesion clearance. Studies also monitored the Partial Clearance Rate, looking at the measurement of 75% or more change in lesion count.

Long-Term Follow-up and Durability of Response

Following the initial treatment period, clinical research for Solaraze also included extended observation studies. Open-label follow-up studies were evaluated in patients to track the long-term status of the treated skin after they stopped using the gel.

Consistency of Evidence and Research Limitations

The research provides context regarding the patterns of change observed in groups of patients, but it does not determine whether an individual will respond similarly. The overall body of evidence includes documentation of several limitations described in the scientific literature. A major limitation noted in research reports is that follow-up durations were limited when considering the long-term nature of AK, with most studies providing extensive data only up to 12 months.

Key Studies & References

  1. Topical diclofenac sodium 3% gel in actinic keratosis: a review of efficacy, patient-reported outcomes, and long-term recurrence rates
  2. NICE Guideline NG85: Actinic keratosis and basal cell carcinoma: assessment and management

Frequently Asked Questions (FAQ)

Common questions about Solaraze (FAQ)

Q: Is it normal to feel a burning or stinging sensation after applying the gel?

According to official product information, application site reactions are commonly reported. These local effects include burning, pain, tingling, and irritation at the site where the gel is applied. This type of reaction is generally expected to be confined to the treatment area.

Q: What is the expected general timeline for improvement after starting treatment?

Official guidelines state that the recommended duration of therapy is typically 60 to 90 days. However, the complete therapeutic effect of the medicine may not be fully apparent until up to 30 days following cessation of the treatment course. This indicates that results can continue to develop for a period after application stops.

Q: What are the warnings about using Solaraze while pregnant or breastfeeding?

Regulatory warnings indicate the gel is contraindicated (should not be used) after 30 weeks of pregnancy due to the potential risk of harm to the fetus. For use during the first two trimesters, or while breastfeeding, official sources suggest only minimal amounts of the active ingredient are expected to get into breast milk. Official information suggests consulting with a healthcare provider regarding any use during these periods.

Q: Why is the medicine formulated as a gel rather than a cream or ointment?

Solaraze is formulated as an aqueous-alcoholic gel. Official product descriptions indicate this specific structure is designed to facilitate the absorption of the diclofenac into the epidermis (the outer layer of skin) where it is needed for treatment. This formulation is intended to maximize localized effect while keeping absorption into the bloodstream low.

Q: What are some potential signs that the gel might be causing a severe skin reaction?

While most skin reactions are mild, official regulatory documents warn of the potential for severe skin events. Signs of a severe reaction can include blistering, peeling, red irritated eyes, an unusual fever, or sores in the mouth. Official documents advise seeking immediate medical attention if these severe signs are noticed.

Q: Should the gel be applied only directly to the affected spots or to a wider area?

Official administration guidelines specify that the gel should be applied gently to the lesion areas. The intent is to adequately cover each lesion within the treatment area. Dosage is calculated based on the size of the lesion site being treated.

Q: Is it possible to have an allergic reaction to a specific inactive ingredient in Solaraze?

Yes, the medicine is contraindicated in patients with a known hypersensitivity (allergic reaction) to the active ingredient, diclofenac, or any components of the drug product. This means an allergic response could be triggered by an inactive ingredient as well as the active one. Official information lists all components of the gel.

Q: What are the factual implications of using more than the recommended amount of the gel?

The maximum daily use for the gel is officially set at 8 grams. While the gel is designed for low systemic absorption, exceeding this limit or the recommended duration of use may increase the risk of systemic side effects. These risks are those associated with the NSAID class of drugs, such as potential serious cardiovascular or gastrointestinal events.

Q: What does 'photosensitivity reaction' mean in simple terms for a patient?

Official documents warn that treated areas must avoid sunlight due to the risk of photosensitivity reactions. Photosensitivity means that your skin develops an extreme sensitivity to natural sunlight or artificial UV light. This may result in an exaggerated sunburn-like reaction in the treated areas.

Q: Is there any evidence about the long-term recurrence of AK after using Solaraze?

Studies and official information indicate that clinical research for Solaraze included extended observation studies to track the long-term status of treated skin. These studies have reported recurrence rates of Actinic Keratosis after the initial treatment period. However, research reports indicate that the long-term follow-up data available is limited, typically extending up to 12 months.

How should Solaraze be stored and disposed of?

Storage and Disposal of Solaraze (Diclofenac Sodium) Gel

Solaraze Gel must be stored at controlled room temperature, specifically between 68 F to 77 F (20 C to 25 C), and should not be stored above 25 C. To maintain product quality, do not freeze the gel, and protect it from excessive heat and moisture.

Container and Stability

Condition Requirement
Container Status Keep in the original container and ensure it is tightly closed after use.
Stability After Opening The gel is stable for six months after first opening the tube.

Safety and Disposal

For safety, the medicine must be stored out of the sight and reach of children.

Official disposal instructions prohibit discarding the unused or expired gel in household trash or down the sink or toilet. The product must be returned to a pharmacy or official drug take-back program for safe pharmaceutical waste disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Solaraze found in:

A-Z Index: